CTOs on the Move

Pyxis Oncology

www.pyxisoncology.com

 
Founded by Longwood Fund, Pyxis Oncology is building a differentiated portfolio of biologics, including antibody-drug conjugates (ADCs) and immunotherapies, to improve the lives of patients with difficult-to-treat cancers. Pyxis is employing site-specific conjugation technology to develop highly stable ADCs with enhanced therapeutic indexes. Pyxis is also advancing a diverse portfolio of immunotherapies that target broad immune regulators as well as novel immune checkpoints identified through its immuno-oncology and cold tumor discovery efforts.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Stephen Monks
Chief Technology Officer Profile

Funding

Pyxis Oncology raised $22M on 07/17/2019

Similar Companies

Sermonix Pharmaceuticals

Sermonix Pharmaceuticals is an Ohio LLC privately held biotechnology company with a targeted focus towards bringing female-specific oncology products through proof of concept, preclinical, and clinical development with a clear regulatory pathway in place. Sermonix was founded in late 2014 by David Portman, MD, a leading clinical researcher and expert in women`s health, menopause and selective estrogen receptor modulators, or SERM therapy.

Tunnell Consulting

Tunnell Consulting is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Calithera

Calithera is discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Tumor metabolism and tumor immunology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients. Our lead product candidate in tumor metabolism, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. We are currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors. In tumor immunology, our lead preclinical program is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Our ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets.

Alta Biomedical Group

Alta Biomedical Group is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Powerpollen

PowerPollen offers a breakthrough, scalable technology to collect, preserve and apply pollen on-demand to help improve the productivity, profitability and sustainability of modern farming practices.